yahoo_financeOriginal article
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Phase 1CDI-988Positive
AI Analysis
Summary
Cocrystal Pharma announced completion of patient dosing in a Phase 1b human challenge study evaluating CDI-988 for norovirus prevention and treatment. The milestone indicates progression in early-stage clinical development.
Clinical Trial Data
Phase
1b
Outcome Details
Last subject dosed in Phase 1b human challenge study
Importance:4/10
Sentiment:
0.30
Phase 1bhuman challenge studynorovirusCDI-988
Related Companies
Read the original article
Published by yahoo_finance on September 9, 2026 11:00 AM